课题基金 / 基金详情

MONOCLONAL ANTIBODIES TO CANCER CELLS

MONOCLONAL ANTIBODIES TO CANCER CELLS
癌细胞单克隆抗体
批准号:
5200941
负责人:
I PASTAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

I PASTAN的其他基金

相似基金

相关文献

中文摘要
翻译
K. Chang开发了一种抗体(Kl),可与许多卵巢发生反应 癌症和间皮瘤。抗原(CAK 1)是一个40 Kd的糖基化 通过PI锚附着于细胞表面的蛋白质。为了获得基因 编码这种抗原,他筛选了一个λ表达文库, 抗体,分离克隆并对这些克隆测序。蛋白质 由这些cDNA编码的是与CAK 1共享表位的胞质蛋白 但可能不是膜蛋白。然而,这种抗原是 在与CAK1相同的细胞中表达,并且可能是同一细胞的成员。 家人使用另一种方法,他最近获得了新的克隆体 其具有CAK 1抗原的膜形式的特征。 博士Chang还比较了单克隆抗体B3与 K1对人类肺癌的作用,并表明B3与许多 肺的非小细胞癌,而K1不。K1与 间皮瘤,而B3没有。因此,这两种抗体可以 可用于肺部肿瘤的鉴别诊断。
英文摘要
K. Chang has developed an antibody (Kl) that reacts with many ovarian cancers and mesotheliomas. The antigen (CAK1) is a 40 Kd glycosylated protein attached to the cell surface by a PI anchor. To obtain the gene encoding this antigen, he has screened a lambda expression library using antibodies, isolated clones and sequenced these clones. The protein encoded by these cDNAs is a cytosolic protein sharing an epitope with CAK1 but is probably not the membrane protein. Nevertheless, this antigen is expressed in the same cells as CAK1 and may be a member of the same family. Using an alternative approach, he has recently obtained new clones which have the characteristics of the membrane form of the CAK1 antigen. Dr. Chang has also compared the reactivity of monoclonal antibody B3 with that of K1 on human lung cancers and has shown that B3 reacts with many nonsmall cell carcinomas of the lung, whereas, K1 does not. K1 reacts with mesotheliomas, whereas, B3 does not. Therefore, these two antibodies can be used in the differential diagnosis of lung tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GENETIC ANALYSIS OF THE MULTIDRUG RESISTANCE PHENOTYPE IN TUMOR CELLS
REGULATION OF GENE ACTIVITY
GENETIC ANALYSIS OF THE MULTIDRUG RESISTANCE PHENOTYPE IN TUMOR CELLS
REGULATION OF GENE ACTIVITY
海外基金